{"content":"<li class=\"n-box-item date-title\" data-end=\"1492228799\" data-start=\"1492142400\" data-txt=\"Monday, December 23, 2019\">Friday, April 14, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3257187\" data-ts=\"1492200411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3257187-fda-rejects-lillys-marketing-application-for-ra-candidate-baricitinib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA rejects Lilly&#39;s marketing application for RA candidate baricitinib</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) has <a href=\"https://seekingalpha.com/pr/16799838-u-s-fda-issues-complete-response-letter-baricitinib\" target=\"_blank\">received </a>a Complete Response Letter &#40;CRL&#41; from the FDA regarding its New Drug Application &#40;NDA&#41; seeking approval of JAK inhibitor baricitinib for the treatment of moderate-to-severe rheumatoid arthritis &#40;RA&#41;. The FDA cited the need for more clinical data to support the optimum doses and additional data to further characterize the safety profile across treatment arms.</li><li>Lilly and co-developer Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) disagree with the agency's conclusions and intend to work with the regulator on a path forward.</li><li>President of Lilly Bio-Medicines Christi Shaw says, &ldquo;We are disappointed with this action. We remain confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate-to-severe RA. We will continue to work with the FDA to determine a path forward and ultimately bring baricitinib to patients in the U.S.&rdquo;</li><li>Lilly says its 2017 guidance will remain unchanged as will its longer-term outlook for the rest of the decade. Incyte is assessing the rejection on its previously announced milestone and R&amp;D expense guidance. Any changes will be discussed during its Q1 earnings call.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3235313-fda-extends-review-period-three-months-lilly-incytes-rheumatoid-arthritis-candidate\" target=\"_blank\">FDA extends review period by three months for Lilly and Incyte's rheumatoid arthritis candidate baricitinib</a> (Jan. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3257187\" data-linked=\"FDA rejects Lilly&#39;s marketing application for RA candidate baricitinib\" data-tweet=\"$LLY $LLY $INCY - FDA rejects Lilly&#39;s marketing application for RA candidate baricitinib https://seekingalpha.com/news/3257187-fda-rejects-lillys-marketing-application-for-ra-candidate-baricitinib?source=tweet\" data-url=\"https://seekingalpha.com/news/3257187-fda-rejects-lillys-marketing-application-for-ra-candidate-baricitinib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":1,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}